Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched ...

Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could ...

The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda.

As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?”  Both approaches ...

Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer.

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.